Hengrui Pharmaceuticals Licenses SHR2554 to Treeline Biosciences
China’s Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced a licensing agreement with US-based Treeline Biosciences,...
Cancer
CSPC Pharmaceutical Licenses ADC SYS6002 to Corbus Pharmaceuticals
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced a licensing agreement with Massachusetts-based Corbus...
Luye Pharma Initiates Phase I Study for BA1106, a CD25 Monoclonal Antibody
China-based Luye Pharma Group (HKG: 2186) has announced the first subject dosing in a Phase...
Zelgen’s ZGGS15 Accepted for NMPA Review as First Global BsAb Filing
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that a clinical trial filing for...
Hengrui’s HER2-Targeted ADC SHR-A1811 Aims for Breakthrough Designation
China’s Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced that its SHR-A1811, an HER2 targeted antibody-drug...
EOC Pharma’s CDK7 Inhibitor EOC237 Accepted for CDE Review
EOC Pharma, a biotech operating out of the US and China, has announced that a...
Nona Biosciences Partners with Mythic Therapeutics for Next-Gen ADCs
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has struck a partnership...
Hinova’s HP530S Accepted for NMPA Review as FAK Inhibitor for Solid Tumors
China-based biopharma Hinova Pharmaceuticals (SHA: 688302) has announced that a clinical trial filing for its...
Qilu Pharmaceutical’s QLS12004 Gains Tacit Clinical Trial Approval
The Center for Drug Evaluation (CDE) website indicates that China-based Qilu Pharmaceutical’s Category 1 chemical...
ImmVira’s MVR-T3011 IT Shows Efficacy in Melanoma Treatment
Shenzhen-based biopharma ImmVira has revealed that its first intra-tumoral injection oncolytic virus (OV) product, MVR-T3011...
Hemay Pharma Completes Series D Financing for Autoimmune and Oncology Drugs
China-based Ganzhou Hemay Pharmaceutical Co., Ltd, an innovative drug developer focused on autoimmune diseases and...
SciClone Pharmaceuticals Files for Hong Kong Market Approval of Danyelza
SciClone Pharmaceuticals Inc. (Nasdaq: SCLN), which became a China-based company after going private in 2017,...
Asieris Partners with ReviR Therapeutics for Urogenital Cancer Research
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has struck a...
Harbour BioMed’s Anti-CCR8 Monoclonal Antibody HBM1022 Receives FDA IND Approval
Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China,...
Gracell’s CAR-T Therapy GC012F Receives FDA IND Approval
Shanghai-based biotech Gracell Biotechnologies has reported receiving Investigational New Drug (IND) approval from the US...
BeiGene Launches Mental Health Program for Cancer Patients
China-based biotech BeiGene (Nasdaq: BGNE; HKG: 6160; SHA: 688235) has announced the launch of a...
AnHeart Therapeutics Partners with Guardant Health for Taletrectinib Diagnostics
Sino-US biopharma AnHeart Therapeutics and US precision oncology firm Guardant Health Inc. (NASDAQ: GH) have...
Grand Pharma’s TLX101 Accepted for NMPA Review for Glioblastoma Treatment
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that an Investigational New Drug (IND)...
Mabwell’s Novel ADC 9MW2921 Accepted for NMPA Review
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that a clinical trial filing...
Roche Reports 2% YOY Growth in 2022; Ocrevus and Hemlibra Drive Sales
Swiss pharmaceutical giant Roche (SWX: RO) released its 2022 financial report this week, recording CHF...